Ipsen S.A. (EPA:IPN)
158.50
-0.70 (-0.44%)
Sep 9, 2026, 5:35 PM CET
Ipsen Employees
Ipsen had 5,535 employees as of December 31, 2025. The number of employees increased by 177 or 3.30% compared to the previous year.
Employees
5,535
Change (1Y)
177
Growth (1Y)
3.30%
Revenue / Employee
€775,303
Profits / Employee
€92,611
Market Cap
13.05B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 5,535 | 177 | 3.30% | 5,535 | 0 |
| Dec 31, 2024 | 5,358 | 33 | 0.62% | 5,358 | 0 |
| Dec 31, 2023 | 5,325 | 253 | 4.99% | 5,325 | 0 |
| Dec 31, 2022 | 5,072 | -672 | -11.70% | 5,072 | 0 |
| Dec 31, 2021 | 5,744 | 41 | 0.72% | 5,744 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| EssilorLuxottica Société anonyme | 213,909 |
| emeis Société anonyme | 84,600 |
| Sanofi | 74,846 |
| Clariane SE | 70,685 |
| Eurofins Scientific SE | 65,000 |
| Ramsay Générale de Santé | 40,000 |
| bioMérieux | 15,226 |
| Sartorius Stedim Biotech | 10,477 |
Ipsen News
- 2 days ago - IPSEN - Buy-back programme - Art 5 of MAR - Week 36- 2025 - GlobeNewsWire
- 19 days ago - Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline - Financial Post
- 5 weeks ago - Ipsen Earnings Call Transcript: Q2 2026 - Transcripts
- 5 weeks ago - Ipsen Earnings release: Q2 2026 - Filings
- 5 weeks ago - Ipsen Slides: Q2 2026 - Filings
- 5 weeks ago - Ipsen Quarterly report: Q2 2026 - Filings
- 6 weeks ago - Ipsen Drug Misses Goal in Late-Stage Trial for Rare Liver Disease - WSJ
- 2 months ago - Drugmaker Ipsen Sees More Deals Coming to Continue Buying Spree - WSJ